Shares of Sun Pharmaceutical Industries Ltd. surged 4.29% to ₹1,723 in early trade on Friday after the company received a major legal win in the U.S. that removes barriers to the launch of its product LEQSELVI™ (deuruxolitinib). The U.S. Court of Appeals for the Federal Circuit vacated the preliminary injunction that had previously delayed the drug’s rollout.
The favorable court order, delivered on April 9, 2025, allows Sun Pharma to go ahead with its market launch strategy in the United States, even as the broader litigation with Incyte Corporation continues. The now-defunct injunction was initially issued by the U.S. District Court for the District of New Jersey, halting LEQSELVI™’s commercial debut.
This development marks a significant milestone for Sun Pharma’s U.S. expansion plans. The company confirmed that it will unveil its detailed launch plans shortly.
At the time of writing, Sun Pharma shares were trading at ₹1,723, up ₹70.80 from the previous close of ₹1,652.20. The stock hit an intraday high of ₹1,733.95 and has a market cap of ₹4.15 trillion. This boost in investor sentiment also pushed Sun Pharma among the top gainers on the NSE today.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
